Diminishing returns, quantified
The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.
Dosing
Page 29 of 31 of this archive, newest first.
How a correct calculation becomes a wrong dose
Almost every case involves a change — a new vial, a new syringe size, a new supplier — carried forward with an old number.
What the new Saudi Arabia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
The dose that got you here and the dose that keeps you here
What the labels permit, what clinicians do, and the size of the gap between them.
What the GLP-1 receptor actually does when mazdutide binds it
Selectivity, potency and efficacy are three different measurements. The trade routinely reports none of them.
South Africa pharmacy body issues counselling standards for dulaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Reflux, early satiety, and the volume the stomach will accept
What scintigraphy and breath-test studies established about emptying rate, and what they did not.
Background rates, and why they matter for attribution
Rapid weight loss by any means raises gallstone risk. Separating that from a direct drug effect requires a comparator, and the trials have one.
What the new Italy guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Site selection when the tissue has already changed
A rotation scheme that is too complicated will not be followed. We describe the simple ones that are.
India pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
From 0.25 to 2.4: reading a ladder as a series of ratios
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
What the new Germany guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
New Zealand pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new the United Arab Emirates guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Randomised withdrawal is the cleanest design in this field and the least discussed
The regain trajectories, arm by arm, with the estimands named.
What the anaesthetists said, and then said again
What endoscopic and ultrasound studies found about residual gastric content, and what the aspiration data does and does not support.
The trade has decided the ceiling is arbitrary. The trials disagree.
The ceiling in this class is anatomical: the same receptor populations that suppress appetite provoke nausea, and they saturate together.
Turkey pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.